Sage Therapeutics – Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions.
The PSYK ETF (NYSE: PSYK) tracks the Enhanced Consciousness Index.
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Where Sage Therapeutics Stands With Analysts
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
SVB Leerink Maintains Market Perform on Sage Therapeutics, Lowers Price Target to $60
SVB Leerink analyst Marc Goodman maintains Sage Therapeutics (NASDAQ:SAGE) with a Market Perform and lowers the price target from $70 to $60.
Sage Therapeutics – Biogen Share One Year Zuranolone 50mg Data In Depression Patients
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have
The Daily Biotech Pulse: Adcom Backs Merck’s Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sage Therapeutics And Biogen Announce One-Year Zuranolone 50 mg Data In Ongoing Open-Label SHORELINE Study
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Kiromic BioPharma (NASDAQ:KRBP) shares increased by 5.26% to $3.0 during Friday's after-market session. The market value of their outstanding shares is at $46.3 million.